Barrigel - Radiotherapy protection spacer

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Available from:

Palette Life Sciences Australia Pty Ltd

Class:

Class III

Manufactured by:

Palette Life Sciences 27 E Cota Street Suite 402, Santa Barbara, CA, 93101 United States Of America

Therapeutic area:

60424 - Radiotherapy protection spacer

Therapeutic indications:

Barrigel is a sterile, transparent, biodegradable gel of stabilized hyaluronic acid of non-animal origin, supplied in a glass syringe. Barrigel acts by adding volume to the tissue, thereby mechanically creating an increased distance between the prostate and the anterior rectal wall. The product degrades over time. Barrigel is used to increase the distance between the prostate and the anterior rectal wall, with the intent to decrease radiation dose delivered to the rectum when treating prostate cancer with radiation.

Authorization status:

A

Authorization date:

2020-07-21